Recent News

By Category: Countermeasures

Drug Helps Beat Ebola Infection if Given Within 48 Hours, Report Says

(Global Security Newswire) An experimental Ebola countermeasure is said to be effective if used within two days of exposure to the virus, a significant step over prior drugs requiring administration within 30 minutes, the Ottawa Citizen reported on Thursday. The medicine functions by hindering Ebola's progression, providing the body a longer period to neutralize the Read More »

June 18, 2012
| Filed under North America, Agents & Toxins, Countermeasures, Public Health, and Research
Share

Reduction Focus Shifts From Nukes to Bio Threats

(American Forces Press Service) WASHINGTON – The 21-year-old program to reduce weapons of mass destruction in the former Soviet Union is shifting focus from nuclear to biological threats and from Russia to Southeast Asia and Africa, the assistant secretary of defense for global strategic affairs told a Senate panel yesterday. Madelyn R. Creedon said the Read More »

June 15, 2012
| Filed under Africa, Asia/Pacific, Europe, North America, South Asia, Biological Weapons, Bioterrorism, Countermeasures, and Policy & Initiatives
Share

Gazette opinion: Absurd federal rule blocks vaccine research

(Billings Gazette) On May 29, Sens. Jon Tester and Max Baucus urged federal research regulators to reconsider restrictions that effectively block research to develop vaccines against brucellosis. The senators and Rep. Denny Rehberg previously have sought to remove this government impediment to important research. The Interagency Bison Management Plan partners asked the Montana delegation to Read More »

June 13, 2012
| Filed under North America, Agriculture, Countermeasures, Policy & Initiatives, and Research
Share

Siga appeals PharmAthene smallpox drug ruling

(CBS News) NEW YORK — Siga Technologies Inc. said Tuesday that it is appealing a ruling that awarded about half the profits on its smallpox drug to PharmAthene Inc. Siga said it filed an appeal to overturn the Delaware Chancery Court decision. The court ruled May 31 that after Siga makes its first $40 million Read More »

June 13, 2012
| Filed under North America, Countermeasures, and Policy & Initiatives
Share

Clinical Trials for Beginners: Ethics – Pediatric Anthrax Vaccine Case Study

(Scientific American) Having looked at the rampant conflicts of interest surrounding the anthrax vaccine and a bit at the logistics of the proposed pediatric vaccine trial let’s look at the trial in the context of ethical principles. The need for ethical guidelines came to vivid attention during World War II, when the Nazis tortured many Read More »